Valuation: Precision BioSciences, Inc.

Market Cap 205M 178M 166M 152M 286M 19.55B 290M 1.96B 765M 9.78B 769M 752M 32.64B P/E 2026 *
-2.05x
P/E 2027 * -2.74x
Enterprise Value 205M 178M 166M 152M 286M 19.55B 290M 1.96B 765M 9.78B 769M 752M 32.64B EV / Sales 2026 *
15.8x
EV / Sales 2027 * 17.6x
Free-Float
93.72%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision BioSciences, Inc.

1 day-1.62%
1 week-2.28%
Current month+4.43%
1 month-16.67%
3 months-10.98%
6 months+84.34%
Current year+75.48%
1 week 7.2
Extreme 7.2
7.76
1 month 6.7
Extreme 6.7
8.96
Current year 3.53
Extreme 3.53
9.62
1 year 3.53
Extreme 3.53
9.62
3 years 3.53
Extreme 3.53
19.43
5 years 3.53
Extreme 3.53
431.4
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Executive Officer 48 2021-10-14
Chief Tech/Sci/R&D Officer 53 2006-01-25
Director of Finance/CFO 45 2026-07-31
Director TitleAgeSince
Chairman 68 2020-10-31
Director/Board Member 65 2020-03-09
Director/Board Member 67 2021-04-11
Date Insider Type Main position Quantity % Market Cap.
8/1/26 Other

Chief Financial Officer

251,581 1.0451%
8/1/26 Other

Controller/Auditor

48,872 0.2030%
8/1/26 Other

Chief Technology Officer

236,188 0.9812%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-2.28%+66.67%-54.52% 205M
+1.17%+2.03%+4.91%+15.74% 48.72B
-1.59%+2.38%+472.89%+573.56% 43.99B
-0.85%+8.70%+23.57%+80.09% 40.82B
-0.08%+2.32%+29.91%+9.86% 39.79B
0.00%+6.15%+23.03%+48.00% 32.7B
-2.52%-0.99%+26.71%+118.05% 16.66B
-3.61%+0.83% - - 16.84B
+0.72%+0.60%+4.97%+21.70% 13.95B
-1.09%+7.88%+84.14%+31.15% 13.58B
Average -0.87%+3.27%+81.87%+93.74% 26.72B
Weighted average by Cap. -0.47%+3.66%+102.31%+135.43%

Financials

2026 *2027 *
Net sales 12.99M 11.26M 10.55M 9.62M 18.11M 1.24B 18.4M 124M 48.51M 620M 48.76M 47.7M 2.07B 11.62M 10.08M 9.45M 8.61M 16.21M 1.11B 16.47M 111M 43.42M 555M 43.64M 42.7M 1.85B
Net income -97.34M -84.38M -79.1M -72.12M -136M -9.29B -138M -931M -364M -4.65B -365M -358M -15.51B -98.96M -85.78M -80.41M -73.32M -138M -9.44B -140M -947M -370M -4.73B -372M -363M -15.77B
Net Debt - -
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Employees
67
Date Price Change Volume
26-08-13 US$7.300 -1.62% 226,765
26-08-12 US$7.420 -1.20% 268,142
26-08-11 US$7.510 +0.67% 345,173
26-08-10 US$7.460 -0.40% 192,067
26-08-07 US$7.490 +0.94% 240,108
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.420USD
Average target price
29.40USD
Spread / Average Target
+296.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DTIL Stock